Clostridioides difficile (C. difficile) represents a serious public health threat, with pharmacists and advocacy organizations playing critical roles in prevention, education, and management.

This single-center, descriptive, retrospective chart review identified barriers to outpatient chemotherapy use, revealing avoidable inpatient stays and highlighting targets for stewardship interventions.

Eli Lilly is expanding access to tirzepatide, a groundbreaking GLP-1 medication for weight management, offering more affordable options for obesity treatment.

Discover the latest FDA-approved treatments, including Dupixent for chronic urticaria and Valtoco for seizure clusters, enhancing patient care options.

Host Craig Beavers chats with Shannon Finks, PharmD, FCCP, BCPS, BCCP, AHSCP-CHC, president and director of pharmacy services at ZupMed in Memphis, Tennessee.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Talquetamab and teclistamab showed significant promise in a phase 1b/2 dose escalation and expansion trial.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Nemolizumab shows promising long-term efficacy in reducing itch and skin lesions for atopic dermatitis, enhancing quality of life for patients.

The subcutaneous infusion is indicated for pediatric patients aged 6 to 17 years who weigh less than 60 kg.

New executive orders and legislation aim to lower prescription drug costs and enhance access to pharmacist services for seniors across the US.

Explore the evolving role of pharmacists in patient care, emphasizing personalized services, community health, and innovative solutions for better health outcomes.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, co-chair of the 2025 Oncology Pharmacists Connect (OPC) meeting, discusses what makes the event unique, highlights key sessions, and shares her excitement for the educational and networking opportunities.

Moderna's mRNA-1345 vaccine gains FDA approval, enhancing protection against RSV for high-risk adults aged 18 to 59, following earlier approvals for older populations.

Ribociclib plus endocrine therapy shows improved survival in HR+, HER2- breast cancer, but its cost-effectiveness raises concerns in the US market.

Vitamin D could offer an alternative option over hard-to-access and burdensome cancer drugs to heighten the response of chemotherapy.

In 3 phase 3 clinical trials, enlicitide decanoate demonstrated clinically significant reductions in low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidemia and familial hypercholesterolemia.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Pharmacists and pharmacy technicians are key to offering more accessible and efficient care.

Ribociclib in combination with a nonsteroidal aromatase inhibitor (NSAI) improved invasive disease-free survival (iDFS) while allowing for better quality of life in hormone receptor-positive (HR+)/human epidermal growth receptor 2-negative (HER2−) early breast cancer.

Results from a systematic review shed light on the role that obesity and overweight play in increasing the severity of symptoms in long COVID.

The investigational blood test achieved 99% sensitivity and specificity.

The data from the 5-year analysis of arm C validate and support the efficacy and safety of zanabrutinib for treatment-naïve patients with CLL/SLL harboring del(17p).

Pharmacists are redefining health care by bridging clinical and economic evidence, making a real difference in patient outcomes through health economics and outcomes research (HEOR).